The Efficacy and Safety of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2
A legfontosabb adatok
- Ki végzi
- Lupin Ltd.
- Hol
- Belgium, Dánia, Egyesült Királyság, Németország, Olaszország és Spanyolország7 helyszín, 6 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Fázis
- 3. fázis
- Résztvevők
- 176 fő, tervezett
- Kezdés
- 2025. febr. 13.
- Várható befejezés
- 2027. jún.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Mexiletine granules for prolonged-release oral suspension
- Placebo
- A regiszteradat frissítve
- 2026. szeptember 24.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for people aged 16 or older with myotonic dystrophy type 1 or type 2, confirmed by a gene test. They must have grip myotonia, which means slow release of the hand after gripping.
- Életkor
- 16 years and older
- Nem
- Male, or female who is not pregnant
- A betegség stádiuma
- DM1 or DM2. Hand grip relaxation is delayed by ≥ 3 seconds after a maximum squeeze. People must be able to walk 10 meters on their own, and a cane, walker or braces are allowed. They need enough finger strength to grip the test handle. DM1 patients need a MIRS muscle score of 2, 3 or 4. BMI must be 18.5 kg/m2 to 30 kg/m2, and weight ≥45 kg (99 lb).
- Korábbi kezelés
- No mexiletine within 4 weeks before Day 1. No other anti-myotonic treatment within 4 weeks before Day 1 or 5 half-lives, whichever is longer. Examples are propafenone, flecainide, lamotrigine and carbamazepine.
- Biomarker vagy leletérték
- DM1 or DM2 confirmed by a genetic test.
A részvétel fő kizáró okai
- Pregnant or breastfeeding
- Serious heart problems, such as conduction blocks, rhythm problems, heart failure, a pacemaker or an ICD
- Severe kidney problems (GFR < 30 mL/min)
- Using a wheelchair or confined to bed, or more than 5 falls in the past 12 months
- Allergy to mexiletine or local anesthetics
A regiszter feltételei, szó szerint
Mind a 27 feltétel megnézéseKevesebb
Ki vehet részt
- DM1 or DM2 diagnosis confirmed genetically
- Ability to comprehend and willingness to sign an informed consent (ICF) or ICF of the parent(s)/legal guardian and written assent from the patient (if patient < 18 years of age)
- Ability to understand the study requirements including intention to stay in the study until the end-of-study visit at 26 weeks of treatment
- Male or non-pregnant female ≥16 years of age
- Body Mass Index (BMI) of 18.5 kg/m2 to 30 kg/m2, and weight ≥45 kg
- Female patients of childbearing potential must be using a highly effective form of birth control for the duration of the study and for at least 7 days after last dose of study drug
- No significant cardiac abnormalities as determined by a cardiologist's assessment
- Have sufficient finger flexor strength to grasp the handle of the dynamometer used to measure myotonia
- Presence of clinical handgrip myotonia (delayed relaxation of grip of ≥ 3 seconds after maximum voluntary contraction) at screening using VHOT
- Be able to walk independently 10 meters (cane, walker, orthoses allowed)
- DM1 patients only - Muscular impairment rating scale (MIRS) score of 2, 3 or 4.-
Ki nem vehet részt
- Have any one of the following medical conditions: uncontrolled diabetes mellitus, cancer other than skin cancer less than five years previously (e.g., basal-cell carcinoma (BCC) and squamous-cell carcinoma (SCC) of skin allowed), multiple sclerosis, seizure disorders, or other serious medical illness
- Treatment with mexiletine within 4 weeks prior to baseline (Day 1)
- Intake of any anti-myotonic treatment within 4 weeks prior to baseline (Day 1) or 5 half-lives, whichever is longer such as metformin, such as propafenone, flecainide, lamotrigine, carbamazepine or any other channel-blocker/ anticonvulsive drugs
- Use of any concomitant medications that could increase the cardiac risk
- Medical conditions which could interfere with muscle function such as infections, trauma, fractures, or planned surgery
- Medical conditions that could affect hand functioning including but not limited to rheumatoid arthritis, Dupuytren's contracture, hand deformity, etc
- Severe arthritis or medical condition (other thanDM1/DM2) that would significantly impact ambulation
- Known allergy to mexiletine or any local anesthetics
- Severe renal impairment (glomerular filtration rate (GFR) < 30 mL/min)
- Preexisting elevated liver function tests > 3 times the upper limit of normal (ULN) at screening (alanine transaminase (ALT)/aspartate transaminase (AST), gamma-glutamyl transferase (GGT)) and/or any abnormal chemistry, hematology or urine lab considered clinically significant by investigator
- Serum potassium values < 3.5 mmol/L or > 5.0 mmol/L or serum magnesium values < 1.7 mg/dL. Electrolytic imbalance such as hypokalaemia, hyperkalaemia or hypomagnesaemia may increase the proarrhythmic effects of mexiletine. Electrolyte imbalances need to be corrected before administering mexiletine and will be monitored throughout treatment
- Any cardiac safety associated condition including any of the following criteria detected by screening cardiac evaluations including 24-hr Holter monitor, echocardiogram and clinical evaluations:; PR interval ≥240 ms or QRS duration ≥120 ms on resting ECG; Personal history of 3rd degree or 2nd degree type 2 atrioventricular block or sinus node dysfunction with pauses ≥3 seconds, complete bundle branch block, bifascicular and trifascicular block or any heart block susceptible to evolve to complete heart block; Personal history of sustained atrial fibrillation, flutter or tachycardia (duration >30 seconds); Personal history of non-sustained (ventricular triplets or more) or sustained ventricular tachycardia; Myocardial infarction (acute or past) or coronary artery stenosis >50%, presence of abnormal Q waves; New York Heart Association (NYHA) Class II to IV heart failure; Left ventricular systolic dysfunction with ejection fraction <50%; Sinus node dysfunction (including ECG sinus rate <50 beats per minute (BPM)); Co-administration of antiarrhythmics inducing torsades de pointes (class Ia: quinidine, procainamide, disopyramide, ajmaline; class Ic: encainide, flecainide, propafenone, moricizine; class III: amiodarone, sotalol, ibutilide, dofetilide, dronedarone, vernakalant); Co-administration of other classes of antiarrhythmics (class Ib: lidocaine, phenytoin, tocainide; class II: propranolol, esmolol, timolol, metoprolol, atenolol, carvedilol, bisoprolol, nebivolol; class IV: verapamil, diltiazem); Patients with implantable cardioverter defibrillators (ICDs) and pacemakers are excluded; Presence of symptomatic coronary artery disease
- Are pregnant or lactating
- High incidence of falls or fall-associated fractures (>5 falls during the past 12 months)
- Participation in another interventional clinical study during the last 3 months or 5 half-lives of the investigational medicinal product, whichever is longer
- Wheelchair-bound or bed-ridden
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
6 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
A Randomized, Double-blind, Placebo-Controlled, Multi-Center Study to Investigate the Efficacy and Safety of Once Daily Mexiletine PR During 26 Weeks of Treatment in Patients with Myotonic Dystrophy Type 1 and Type 2 (HERCULES study)
A teljes eredeti leírásKevesebb
Study website: https://myotonicdystrophystudy.com/
A vizsgálat 2 csoportja
- PlaceboPlacebo, összehasonlításként
0 mg (matching sachet volumes to low, medium and high dose active drug)
- Mexiletine prolonged-release (PR)Már használt kezelés, összehasonlításként
Mexiletine PR 167 mg (mexiletine HCl 200 mg) Mexiletine PR 333 mg (mexiletine HCl 400 mg) OR Mexiletine PR 500 mg (mexiletine HCl 600 mg)
Kezelés: Mexiletine granules for prolonged-release oral suspension
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Investigate the Efficacy and Safety of Once Daily Mexiletine PR During 26 Weeks of Treatment in Patients With Myotonic Dystrophy Type 1 and Type 2 (Phase 3)
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
- A regiszteradat frissítve
- 2026. szeptember 24.